The Disruptive Technologies Innovation Fund, a major driver of Impact 2030 research and innovation strategy, has awarded Amara Therapeutics funding for RiSolve - a safe and effective personalised therapy that will disrupt the overactive bladder treatment market using an innovative artificial intelligence-based digital platform.
Read the Departmental Press Release
Read more on Silicon Republic
Recent News
- Making it Work: Avoiding delicate situations with the aid of a digital platform 07 April 2022
- Amara features in Enterprise Ireland Big Ideas Event 22 September 2022
- Cookie Policy 22 November 2022
- Amara Therapeutics DTIF Funding Success 17 November 2022
- Amara Therapeutics Runner-up Finalists in EIT Health Catapult 22 September 2022